Search Result

Results for "

brd4+protac

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Bcl-2 Family (1) c-Myc (5) Caspase (1) Drug-Linker Conjugates for ADC (1) E3 Ligase Ligand-Linker Conjugates (4) Epigenetic Reader Domain (39) HIV (1) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (2) PD-1/PD-L1 (1) PROTAC Linkers (1) PROTACs (32) Proteasome (1) Proteasome Cap Targeting Chimeras (1) Reference Standards (1)
By Research Areas:	Cancer (40) Infection (1) Inflammation/Immunology (2) Neurological Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-129937A

GNE-987 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
GNE-987 is a VHL-dependent *BRD4 PROTAC* degrader. GNE-987 exhibits picomolar cell *BRD4* degradation activity (DC₅₀=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC₅₀=4.7 and 4.4 nM, respectively). GNE-987 can be used for the research of cancer .

HY-149878

BD-9136	PROTACs Epigenetic Reader Domain	Cancer
BD-9136 is a potent and highly selective *BRD4 PROTAC* depressant. BD-9136 has low-nanomolar degradation potencies against *BRD4* , and its degradation selectivity for BRD4 is 1000 times that of BRD2 and BRD3 proteins. BD-9136 has antitumor activity .(Pink: Desmethyl-QCA276 (HY-44103); Black: 3-(2-(4-Methylpiperazin-1-yl)ethyl)azetidin-3-ol; Blue: Thalidomide-4-OH (HY-103596))

HY-114406

TD-106	Ligands for E3 Ligase	Cancer
TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation .

HY-132941

CFT-2718	PROTACs Epigenetic Reader Domain c-Myc Apoptosis	Cancer
CFT-2718 is a selective CRBN-dependent *BRD4 PROTAC* degrader. CFT-2718 mediates rapid, selective BRD4 degradation, reduces total and phosphorylated Ser2 RPB1 levels, and reduces MYC protein levels. CFT-2718 can inhibit cancer cells proliferation and induce apoptosis. CFT-2718 reduces growth of lung cancer and pancreatic patient-derived xenograft models. CFT-2718 can be used for the research of cancer, such as small-cell lung cancer and pancreatic cancer .

HY-107442

PROTAC BRD4-binding moiety 1	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136) . PROTAC BRD4-binding moiety 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-164995

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a *BRD4 PROTAC* degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .

HY-174996

NEP162	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
NEP162 is a *BRD4 PROTAC* degrader with DC₅₀s of 1.2 and 1.6 μM in SW480 and U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibits tumor growth and induces apoptosis. NEP162 can be used for the study of osteosarcoma, colorectal cancer and non-small cell lung cancer, etc. (Pink: BRD4 ligand : (HY-78695), Blue: E3 ligase Ligand (HY-D2259), BLACK: Linker, E3 ligase ligand-linker conjugate (HY-174997)) .

HY-161651A

BRD4 ligand 6 TFA	Epigenetic Reader Domain	Cancer
BRD4 ligand 6 TFA is the TFA salt form of BRD4 ligand 6 (HY-161651). BRD4 ligand 6 TFA is a *BRD4* ligand and can be used for synthesis of BRD4 PROTACs, such as PROTAC BRD4 Degrader-26 (HY-161650) .

HY-131203

PROTAC BRD4 Degrader-6	PROTACs Epigenetic Reader Domain Apoptosis c-Myc Caspase	Cancer
PROTAC BRD4 Degrader-6 (compound 32a) is a potent small-molecule *BRD4*PROTAC degrader with IC₅₀ value of 2.7 nM for BRD4 BD1. PROTAC BRD4 Degrader-6 potently degrades BRD4 protein and inhibits the expression of c-Myc. PROTAC BRD4 Degrader-6 inhibits the proliferation of pancreatic cancer cell line BxPC3 and induces apoptosis. PROTAC BRD4 Degrader-6 can be used for human pancreatic cancer research (Pink: Mivebresib (HY-100015); Black: linker, Azido-PEG1-CH2CO2H (HY-108369); Blue: Lenalidomide (HY-A0003)) .

HY-174210

PROTAC BRD4 Degrader-31	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-31 is a *BRD4* PROTAC degrader with DC₅₀ s of 164 and 80 nM at 4 h and 24 h, respectively. PROTAC BRD4 Degrader-31 potently degrades BRD4 in cells with long acting degradation kinetics . Pink: BRD4 ligand (HY-78695); Blue: KLHDC2 ligand (HY-174218)

HY-161651

BRD4 ligand 6	Epigenetic Reader Domain	Cancer
BRD4 ligand 6 is a *BRD4* ligand and can be used for synthesis of BRD4 PROTACs, such as PROTAC BRD4 Degrader-26 (HY-161650) .

HY-175224

PROTAC BRD4 Degrader-36	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-36 is a *BRD4 PROTAC* degrader. PROTAC BRD4 Degrader-36 has a DC₅₀ of 0.649 nM and a D_max of 71% in PANC-1 cells. PROTAC BRD4 Degrader-36 is cytotoxic to PANC-1 cells (GI₅₀: 0.103 μM). PROTAC BRD4 Degrader-36 can be used in the study of cancer. (Pink: PROTAC BRD4 ligand-1 (HY-129939); Blue + Black: E3 ligase ligand + linker (HY-175241)) .

HY-174811

PROTAC BRD4 Degrader-33	PROTACs Epigenetic Reader Domain PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC BRD4 Degrader-33 is an enzyme activated clickable *BRD4* PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model . Pink: BRD4 ligand (HY-174812); Blue: CRBN ligase ligand (HY-10984); Black: linker

HY-177041

PROTAC BRD4 Degrader-35	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-35 (Compound 17) is a PROTAC degrader of *BRD4*. PROTAC BRD4 Degrader-35 can be studied in anticancer research. (Pink: BRD4 ligand (HY-78695); Black: linker; Blue: ligase) .

HY-138635

PROTAC BRD4 Degrader-12	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4*. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 0.39 nM and 0.24 nM, respectively .

HY-138633

PROTAC BRD4 Degrader-10	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and *BRD4*. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC₅₀ of 1.3 nM and 18 nM, respectively .

HY-174975

JY-21	PROTACs Epigenetic Reader Domain	Cancer
JY-21 is a *BRD4* PROTAC degrader with a DC₅₀ of 3.797 μM. JY-21 has a potent anticancer activity against MDA-MB-231 cells . Pink: BRD4 ligand (HY-78695); Blue: E3 ligase ligand (HY-174994); Black: linker (HY-151862)

HY-177730

PROTAC BRD4 Degrader-40	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-40 is a Bromodomain protein 4 (BRD4) PROTAC degrader. PROTAC BRD4 Degrader-40 can induce BRD4 degradation in cancer cells. PROTAC BRD4 Degrader-40 can be used for the research of cancer, such as leukemia . (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: CRBN ligand (HY-163927))

HY-175240

PROTAC BRD4 Degrader-38	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-38 is a *BRD4* PROTAC degrader with DC₅₀s of 86 and 106 nM for the short and long isoforms of BRD4, respectively. PROTAC BRD4 Degrader-38 significantly induces the degradation of BRD4 by covalently engaging C232 of E3 ligase TRIM28 .Pink: BRD4 ligand (HY-78695); Blue: E3 ligase ligand (HY-203082); Black: linker (HY-40172)

HY-174920

PROTAC BRD4 Degrader-34	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-34 (Compound MZ2) is a selective *BRD4 PROTAC* degrader (pDC₅₀ = 8.4). PROTAC BRD4 Degrader-34 can induce BD2 degradation mediated by VHL. PROTAC BRD4 Degrader-34 can be used for research on cancer. (Pink: BRD4-BD2 Ligand (HY-78695); Blue: VHL Ligand (HY-125845); Black: Linker (HY-130524)) .

HY-153519

WWL0245	Epigenetic Reader Domain	Cancer
WWL0245 is a potent and seletive *BRD4* PROTAC. WWL0245 selectively degrades BRD4 with sub-nanomolar DC₅₀ (<1 nM) than BRD2/3 and PLK1 ( DC₅₀>1 μM). WWL0245 shows excellent selective cytotoxicity in the BETi sensitive cancer cell lines, including AR-positive prostate cancer cell lines. WWL0245 is a promising drug candidate for AR-positive prostate cancer research and a valuable tool compound to study the biological function of BRD4 .

HY-178510

JQ1-S(GlcNAc)Cq	PROTACs Epigenetic Reader Domain	Cancer
JQ1-S(GlcNAc)Cq is a sugar-coated *BRD4* PROTAC degrader. JQ1-S(GlcNAc)Cq can inhibit the formation of the ternary complex between CRBN and BRD4(BD1/BD2). JQ1-S(GlcNAc)Cq can be used for the research of cancer . (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: CRBN ligand (HY-178514); Black: linker (HY-W105727); BRD4 ligand-Linker: (HY-178519))

HY-176449

PROTAC BRD4 Degrader-32	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-32 (Compound 22) is a *BRD4* PROTAC degrader (DC₅₀: 0.20 nM). PROTAC BRD4 Degrader-32 connects the BRD4-binding domain and CRBN-binding domain through a unique carbon-carbon linked linker to form a ternary complex, inducing ubiquitination of BRD4 for proteasomal degradation. PROTAC BRD4 Degrader-32 is promising for research of BRD4-related cancers (such as hematological malignancies). (Pink: GSK1324726A (HY-13960); Black: linker (HY-176450); Blue: Lenalidomide-5-Br (HY-W072954)) .

HY-176035

MS479	PROTACs Epigenetic Reader Domain	Cancer
MS479 is a *BRD4 PROTAC* degrader. MS479 binds BRD4-BD2 and GLP with high affinities (BRD4-BD2: K_d = 200 nM; GLP: K_d = 306 nM). MS479 can reduce the protein level of BRD4 short isoform. MS479 recruits the E3 ligase SPOP by directly binding its substrate GLP as a bridge protein. MS479 can be used to inhibit the proliferation of colorectal cancer cells. (Pink: BRD4 ligand (HY-78695); Blue: GLP ligand (HY-176036); Black: linker (HY-176037); GLP ligand+linker: HY-176038) .

HY-175767

PROTAC BRD4 Degrader-39	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-39 is a selective targeting Bromodomain protein 4 (BRD4) degrader with an DC₅₀ value of 24.66 nM. PROTAC BRD4 Degrader-39 conjugates BRD PROTAC (ARV-771) (HY-100972) with carbohydrate. PROTAC BRD4 Degrader-39 selectively delivers to tumor cells with high GLUT1 expression, followed by GSH-triggered release of ARV-771 and degrades BRD4. PROTAC BRD4 Degrader-39 can inhibit tumor growth and show no significant toxicity. PROTAC BRD4 Degrader-39 can be used for the research of cancer, such as breast cancer . (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: VHL ligand (HY-112078); Black: (HY-42427); BRD4 ligand-Linker: (HY-42429))

HY-162240

SJH1-51B	PROTACs Epigenetic Reader Domain	Cancer
SJH1-51B is a SKP1-recruiting *BRD4 PROTAC* degrader. SJH1-51B binds to SKP1 in the SKP1-FBXO7-CUL1-RBX1 complex, but shows no or weak binding to monomeric SKP1. SJH1-51B induces proteasome- and SKP1-dependent degradation of *BRD4, and this degradation process relies on the neddylation modification of Cullin-RING E3* ligase. SJH1-51B induces proteasome-mediated degradation of the short isoform of *BRD4* in non-cancer cells, while it induces proteasome-mediated degradation of both the long and short isoforms of *BRD4* in breast cancer cells. SJH1-51B can be used for breast cancer research .

HY-168692

3-(2-(4-Methylpiperazin-1-yl)ethyl)azetidin-3-ol	PROTAC Linkers	Others
3-(2-(4-Methylpiperazin-1-yl)ethyl)azetidin-3-ol is a linker for BRD4 PROTAC BD-9136 (HY-149878) .

HY-170383

CCW16-C4-NHBoc	E3 Ligase Ligand-Linker Conjugates	Others
CCW16-C4-NHBoc (RNF4 ligand CCW16 (HY-143346)) is an E3 Ligase Ligand-Linker Conjugate for *BRD4* PROTAC CCW 28-3 (HY-156774) .

HY-157561

K2-B4-3e	PROTACs Epigenetic Reader Domain	Cancer
K2-B4-3e is a potent *BRD4* PROTAC. K2-B4-3e induces BRD4 degradation with a DC₅₀ value of 66 nM .

HY-174997

PFI-7-O-C4-piperazin	E3 Ligase Ligand-Linker Conjugates	Cancer
PFI-7-O-C4-piperazin is a E3 ligase ligand-linker conjugate that can be used for synthesis of PROTACs, such as NEP162 (HY-174996). The E3 ligase ligand (PFI-7) of NEP162 is a highly selective antagonist of GID4 (K_D = 0.22 μM). NEP162 is a BRD4 PROTAC degrader with anti-tumor activity ^{[1] ^.}

HY-170808

PROTAC BRD4 Degrader-28	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-28 (Compound 4) is a PROTAC degrader targeting *BRD4*. PROTAC BRD4 Degrader-28 is promising for research of cancers (Pink: target protein ligand JQ-1 (carboxylic acid) (HY-78695); Black+ Blue: E3 ubiquitin ligase ligand-Linker conjugate Thalidomide-O-amido-C3-NH2 (HY-115560)) .

HY-173433

JV8	Epigenetic Reader Domain	Cancer
JV8 is a *BRD4* PROTAC degrader. JV8 promotes the ubiquitination and degradation of BRD4 and induces apoptosis. JV8 has antitumor activity in a mouse 4T1 orthotopic tumor model. (Pink: BRD4 ligand (HY-78695); Blue: E3 ligase VHL ligand (HY-173435); Black: Linker (HY-33366); E3 ligase VHL ligand-linker conjugate (HY-173436)) .

HY-182801

PROTAC BRD4 Degrader-46	PROTACs Epigenetic Reader Domain c-Myc	Cancer
PROTAC BRD4 Degrader-46 is a heterobifunctional *BRD4* PROTAC degrader. PROTAC BRD4 Degrader-46 binds to both *BRD4* and CRBN, thereby triggering ubiquitination and proteasomal degradation of *BRD4*. PROTAC BRD4 Degrader-46 downregulates the levels of downstream BRD2, BRD3 and MYC. PROTAC BRD4 Degrader-46 can be used in the research of cancers such as multiple myeloma .

HY-181553

PROTAC BRD4 Degrader-44	PROTACs Epigenetic Reader Domain	Others
PROTAC BRD4 Degrader-44 is a *BRD4 PROTAC* degrader with a DC₅₀ of 16 nM. PROTAC BRD4 Degrader-44 is applicable to studies on membrane-permeable PROTACs .

HY-179735

CRBN ligand-192	Ligands for E3 Ligase	Cancer
CRBN ligand-192 is an E3 ligand that can be used for the synthesis of PROTACs, such as PROTAC BRD4 Degrader-41 (HY-179734). PROTAC BRD4 Degrader-41 is a potent *BRD4 PROTAC* degrader with anti-cancer activity .

HY-181553A

PROTAC BRD4 Degrader-45	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-45 (Compound 2b) is a PROTAC degrader targeting *BRD4*. PROTAC BRD4 Degrader-45 exhibits enhanced passive membrane permeability, stability in cell culture medium supplemented with 10% FBS, and higher intracellular concentrations in cancer cells .

HY-169401

L321-NH-C3-PEG3-C1-NH2	E3 Ligase Ligand-Linker Conjugates	Others
L321-NH-C3-PEG3-C1-NH2 (CRBN ligand L321 (HY-169359)) is an E3 Ligase Ligand-Linker Conjugate for *BRD4* PROTAC L134 (HY-169358) .

HY-180957

NEP108	PROTACs Epigenetic Reader Domain	Cancer
NEP108 is a GID4 E3 ligase-based *BRD4 PROTAC* degrader, with its DC₅₀ value approximately 3.8 μM. NEP108 has a strong affinity for GID4, with a K_D value of 0.22 μM, and the K_D value of its trimeric complex is 2.85 μM. NEP108 can be used for cancer research .

HY-181495

RAJQ14	Proteasome Cap Targeting Chimeras PROTACs Proteasome Epigenetic Reader Domain	Cancer
RAJQ14 is a *BRD4* PROTAC-like CAP-TAC (Proteasome Cap Targeting Chimeras) degrader. RAJQ14 binds to 19S proteasome cap subunits RPN1, RPN10, RPN13, and USP14 to recruit target proteins to the proteasome for ubiquitination-independent, proteasome-dependent degradation. RAJQ14 can be used for the research of cancer (Pink: BRD4 Ligand (HY-181496); Blue: Proteasome Ligand (HY-128978); Black: Linker).

HY-180150

PROTAC BRD4 Degrader-42	Epigenetic Reader Domain c-Myc Bcl-2 Family Apoptosis	Cancer
PROTAC BRD4 Degrader-42 (Compound P6) is a PROTAC-based *BRD4* degrader with a DC₅₀ of 1.11 μM. PROTAC BRD4 Degrader-42 promotes the ubiquitination and degradation of BRD4. PROTAC BRD4 Degrader-42 downregulates c-Myc expression and induces Apoptosis by upregulating BAD and BAX protein expression. PROTAC BRD4 Degrader-42 also exhibits anticancer activity against myeloid monocytic leukemia .

HY-179734

PROTAC BRD4 Degrader-41	PROTACs Epigenetic Reader Domain Apoptosis c-Myc	Cancer
PROTAC BRD4 Degrader-41 (Compound A5) is a *BRD4 PROTAC* degrader with a DC₅₀ of 0.97 nM. PROTAC BRD4 Degrader-41 exhibits potent anti-proliferative activity against various types of cancer cells such as AML, lymphoma, breast cancer, ovarian cancer, and non-small cell lung cancer. PROTAC BRD4 Degrader-41 can induce G0/G1 phase arrest and apoptosis in MV4-11 cells. PROTAC BRD4 Degrader-41 downregulates the transcriptional level of c-Myc .

HY-180889

PROTAC BRD3 degrader-1	PROTACs Epigenetic Reader Domain	Neurological Disease Inflammation/Immunology
PROTAC BRD3 degrader-1 (compound D072) is a potent and selective PROTAC BRD3 degrader. PROTAC BRD3 degrader-1 selectively degrades BRD3 in mice, leading to the downregulation of H3K18ac without affecting BRD2 or *BRD4*. PROTAC BRD3 degrader-1 reduces intraocular inflammation in the experimental autoimmune uveitis (EAU) mouse mode and inhibits proinflammatory microglia in both uveitis retina and LPS (HY-D1056) treated mouse microglia cell line BV2. PROTAC BRD3 degrader-1 can be used for uveitis research .

HY-183575

JQ1-JX5	PROTACs Epigenetic Reader Domain	Cancer
JQ1-JX5 is a DCAF16-based *BRD4 PROTAC* degrader. JQ1-JX5 covalently modifies Cys58 of DCAF16, promotes ternary complex formation with BRD4, enables BRD4 ubiquitination and proteasomal degradation. JQ1-JX5 induces time-dependent degradation of BRD4 long and short isoforms in AGS cells with DC₅₀ of 43.97 and 16.77 nM. JQ1-JX5 can be used for the research of cancer, such as acute myeloid leukemia .

HY-107442R

PROTAC BRD4-binding moiety 1 (Standard)	Reference Standards Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
PROTAC BRD4-binding moiety 1 (Standard) is the analytical standard of PROTAC BRD4-binding moiety 1 (HY-107442). This product is intended for research and analytical applications. PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136) . PROTAC BRD4-binding moiety 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-181868

Lenalidomide-CO-C7-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-CO-C7-NH2 is a CRBN-dependent intermediate of BET PROTAC degrader. Consisting of the E3 ubiquitin ligase ligand Lenalidomide (HY-A0003) conjugated with a PROTAC linker, Lenalidomide-CO-C7-NH2 induces the protein degradation. By depleting BRD4, PROTAC BET Degrader-16 effectively inhibits cancer cell proliferation, induces cell cycle arrest and promotes apoptosis, thereby exhibiting significant anti-tumor activity in xenograft models. Lenalidomide-CO-C7-NH2 serves as an important tool molecule for the study of acute myeloid leukemia .

HY-181164

PROTAC BRD4 Degrader-43	PROTACs Epigenetic Reader Domain HIV	Infection
PROTAC BRD4 Degrader-43 is a *BRD4 PROTAC* degrader. PROTAC BRD4 Degrader-43 recruits the DCAF1-DDB1-Cul4A E3 ligase complex via a Vpr-derived peptide moiety to induce BRD4 ubiquitination and degradation through the ubiquitin-proteasome system. PROTAC BRD4 Degrader-43 exhibits potent HIV latency-reversing activity. PROTAC BRD4 Degrader-43 can be used for the research of HIV-1 latent infection . (Pink: BRD4 ligand (HY-13030); Blue: Cul4A-DDB1-DCAF1 ligand (HY-P11640); Black: conjugate of PEG linker + cell-penetrating peptide (HY-P2483))

Cat. No.	Product Name		Classification

HY-107442

PROTAC BRD4-binding moiety 1		Alkynes
PROTAC BRD4-binding moiety 1 is a ligand for BRD4. PROTAC BRD4-binding moiety 1 binds to cereblon ligand via a linker to form PROTAC to degrade BRD4 (HY-133136) . PROTAC BRD4-binding moiety 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: